Keywords: sb, infanrix, shows, enhanced, efficacy, major, niaid
SB's Infanrix Shows Enhanced Efficacy In Major NIAID Studies
Article | 24 July 1995
The efficacy of Infanrix, SmithKline Beecham's new acellular pertussis vaccine, was confirmed in a land-mark, placebo-controlled clinical trial carried out ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
